Phebra Pty Ltd

3 PBAC submissions on file, active 2009–2015. 33% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Arsenic trioxide
  Haematology · Not recommended · 2015—
• Colistimethate sodium
  Respiratory · Not recommended · 2011—

Therapy area mix

Activity by year

2009 (1) · 2011 (1) · 2015 (1)

Rejection patterns

Across 2 Not recommended decisions on file.

• 1×uncertain effectiveness in high-risk patients (single-arm studies with high risk of bias)
• 1×comparator regimen (APML3) did not represent current Australian clinical practice
• 1×potential inappropriate initiation of ATO in PML/RAR-α negative patients
• 1×insufficient evidence regarding maximum duration of induction therapy
• 1×regimens in APML4 not simply addition of ATO to APML3